Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) shares fell 4.2% during mid-day trading on Friday . The company traded as low as $23.71 and last traded at $23.79. 9,394 shares were traded during trading, a decline of 95% from the average session volume of 171,124 shares. The stock had previously closed at $24.83.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the company. Stifel Nicolaus started coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a "buy" rating and a $35.00 target price for the company. Jefferies Financial Group started coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a "buy" rating and a $35.00 target price on the stock. Finally, TD Cowen initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, July 2nd. They issued a "buy" rating for the company.
Check Out Our Latest Research Report on Rapport Therapeutics
Rapport Therapeutics Stock Performance
The stock has a 50 day moving average of $21.48.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($1.02). Analysts anticipate that Rapport Therapeutics will post -3.46 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in Rapport Therapeutics in the 2nd quarter worth $17,403,000. Millennium Management LLC purchased a new position in Rapport Therapeutics during the 2nd quarter valued at about $2,716,000. ARCH Venture Management LLC bought a new position in Rapport Therapeutics during the 2nd quarter valued at approximately $86,730,000. TD Asset Management Inc purchased a new stake in Rapport Therapeutics in the 2nd quarter worth approximately $2,361,000. Finally, Johnson & Johnson bought a new stake in shares of Rapport Therapeutics in the 2nd quarter worth approximately $58,105,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
